Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study of Pharmacokinetics, Safety and Tolerability of Drug DD217, Enteric-coated Tablets, 10 mg, Developed by PharmaDiall Ltd (Moscow), on Healthy Volunteers Receiving Single Dose in Fasting State (Phase I)

NCT05181241 is registered in ClinicalTrials.gov with PharmaDiall Ltd. as lead sponsor.

NCT NCT05181241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05181241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study of Pharmacokinetics, Safety and Tolerability of Drug DD217, Enteric-coated Tablets, 10 mg, Developed by PharmaDiall Ltd (Moscow), on Healthy Volunteers Receiving Single Dose in Fasting State (Phase I)
Lead sponsor
PharmaDiall Ltd.
Phase
Phase 1
Overall status
Completed
Start date
January 25, 2017
Completion date
April 25, 2018
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers